Medications References

0

Medications References:

2005

Carmichael SL, Shaw GM, Laurent C , Croughan MS, Olney RS, Lammer EJ. Maternal progestin intake and risk of hypospadias. Arch Pediatr Adolesc Med 2005;159:957-62.
Ref ID: 283

2001

Croen LA, Todoroff K, Shaw GM. Maternal exposure to nitrate from drinking water and diet and risk for neural tube defects. American Journal of Epidemiology 2001; 153(4):325-331

1999

Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. American Journal of Medical Genetics 1999; 86:242-244

1996

Torfs CP, Katz EA, Bateson TF, Lam PK, Curry CJR. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996; 54(2):84-92

1995

Shaw GM, Lammer EJ, Velie EM. Ovulation induction by clomiphene and neural tube defects (letter). Reproductive Toxicology 1995;9(4):399-400

Lammer EJ, Armstrong D. Malformations of hindbrain structures among humans exposed to isotretinoin (13-cis-retinoic acid) during early embryogenesis. In: Morris-Kay G (Ed), Retinoids in Normal Development and Teratogenesis. Oxford: Oxford University Press 1992

Adams J, Lammer EJ. Relationship between dysmorphology and neuropsychological function in children exposed to isotretinoin in utero. In: Fuji T, Boer GJ (Eds), Functional Neuroteratology-Short Term Exposure to Drugs. Tokyo:Teikyo Univ. Press, 1991;159-170

Lammer EJ. Preliminary observations on isotretinoin-induced ear malformations and pattern formation of the external ear. Journal of Craniofacial Genetics and Developmental Biology 1991; 11:292-295

Rizzo R, Lammer EJ, Parano E, Pavone L, Argyle JC. Limb reduction defects in humans associated with prenatal isotretinoin exposure. Teratology 1991; 44:599-604

Lynberg MC, Khoury MJ, Lammer EJ, Waller KO, Cordero JF, Erickson JD. Sensitivity, specificity, and positive predictive value of multiple malformations in isotretinoin embryopathy surveillance. Teratology 1990; 42:513-519

Kraft JC, Nau H, Lammer E, Olney A. Embryonic retinoid concentrations after maternal intake of isotretinoin (letter). New England Journal of Medicine 1989; 321:262

Lammer EJ. Embryopathy in infant conceived one year after termination of maternal etretinate (letter). Lancet 1988 Nov 5; 2(8619):1080-1081

Lammer EJ. Accutane and public-health risk (letter). Wall Street Journal 1986, Jun 16

Lammer EJ, Schunior A, Hayes AM, Holmes LB. Isotretinoin dose and teratogenicity (letter). Lancet 1988; ii :503-4.

Lammer EJ, Hayes AM. Isotretinoin phenocopy.
American Journal of Medical Genetics 1988 Mar; 29(3):675-8

Lammer EJ. Developmental toxicity of synthetic retinoids in humans. Progress in Clinical Biology Research 1988; 281:193-202

Lammer EJ. Developmental toxicity of synthetic retinoids in humans. In: Migaki G, Scarpelli DG, eds. Progress in Clinical and Biological Research, 1988 Vol.281: “Transplacental Effects of Fetal Health.” New York:Alan R. Liss:193-202

Lammer EJ. Patterns of malformation among fetuses and infants exposed to retinoic acid (Isotretinoin). Banbury Report 26: Developmental Toxicology: Mechanisms, and Risk 1988; 26: 243-255.

Downloadable study summary:

pdf_logo-9506575 Gastroschisis and Medications